Literature Cited

  • 1
    Reichert J,Rosensweig C,Faden L,Dewitz M. Monoclonal antibody successes in the clinic. Nat Biotechnol. 2005; 23: 10731078.
  • 2
    Wurm F. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004; 22: 13931398.
  • 3
    Butler M. Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl Microbiol Biotechnol. 2005; 68: 283291.
  • 4
    Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog. 2005; 21: 1116.
  • 5
    Jefferis R. Glycosylation of human IgG. Relevance to therapeutic applications. Biopharm Int. 2001; 14: 1927.
  • 6
    Boyd P,Lines AC,Patel AK. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol. 1995; 32: 13111318.
  • 7
    Shields RL,Lai J,Keck R,O'Connell LY,Hong K,Meng YG,Weikert SH,Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody dependent cellular cytotoxicity. J Biol Chem. 2002; 277: 2673326740.
  • 8
    Shinkawa T,Nakamura K,Yamane N,Shoji-Hosaka E,Kanda Y,Sakurada M,Uchida K,Anazawa H,Satoh M,Yamasaki M,Hanai N,Shitara K. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003; 278: 34663473.
  • 9
    Tsuchiya N,Endo T,Mastsuta K,Yoshinoya S,Aikawa T,Kosuge E,Takeuchi F,Miyamoto T,Kobaka A. Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. J Rheumatal. 1989; 16: 285290.
  • 10
    Wright A,Morrison SL. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 Antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol. 1998; 160: 33933402.
  • 11
    Hodoniczky J,Zheng YZ,James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog. 2005; 21: 16441652.
  • 12
    Kaneko Y,Nimmerjahn F,Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006; 313: 670673.
  • 13
    Scallon BJ,Tam SH,McCarthy SG,Cai AN,Raju TS. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol. 2007; 44: 15241534.
  • 14
    Wright A,Sato Y,Okada T,Chang KH,Endo T,Morrison SL. In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology. 2000; 10: 13471355.
  • 15
    Zhu L,van de Lavoir M-C,Albanese J,Beenhouwer DO,Cardarelli PM,Cuison S,Deng DF,Deshpande S,Diamond JH,Green L,Halk EL,Heyer BS,Kay RM,Kerchner A,Leighton PA,Mather CM,Morrison SL,Nikolov ZL,Passmore DB,Pradas-Monne A,Preston BT,Rangan VS,Shi M,Srinivasan M,White SG,Winters-Digiacinto P,Wong S,Zhou W,Etches RJ. Production of human monoclonal antibody in eggs of chimeric chickens. Nat Biotech. 2005; 23: 11591169.
  • 16
    Chung CH,Mirakhur B,Chan E,Le QT,Berlin J,Morse M,Murphy BA,Satinover SM,Hosen J,Mauro D,Slebos RJ,Zhou Q,Gold D,Hatley T,Hicklin DJ,Platts-Mills TAE. Cetuximab-Induced Anaphylaxies and IgE Specific for Galactose-{alpha}-1,3-Galactose. N Engl J Med. 2008; 358: 11091117.
  • 17
    Raju TS. Glycosylation variations with expression systems and their impact on biological activity of therapeutic immunoglobulins. Bioprocess Int. 2003; 4: 4453.
  • 18
    Browne SM,Al-Rubeai M. Selection methods for high-producing mammalian cell lines. Trends Biotechnol. 2007; 25: 425432.
  • 19
    Kunkel JP,Jan DCH,Jamieson JC,Butler M. Dissolved oxygen concentration in serum-free continuous culture affects N-linked glycosylation of a monoclonal antibody. J Biotechnol. 1998; 62: 5571.
  • 20
    Schmelzer AE,Miller WM. Hyperosmotic stress and elevated pCO2 alter monoclonal antibody charge distribution and monosaccharide content. Biotechnol Prog. 2002; 18: 346353.
  • 21
    Muthing J,Kemminer SE,Conradt HS,Sagi D,Nimtz M,Karst U,Peter-Katalinic J. Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24. Biotechnol Bioeng. 2003: 83: 321334.
  • 22
    Patel T,Parekh RB,Moellering BJ,Prior CP. Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody. Biochem J. 1992; 285: 839845.
  • 23
    Rendall MH,Maxwell A,Tatham D,Khan P,Gay RD,Kallmeier RC,Wayte JRT,Racher AJ. Transfection to manufacturing: reducing timelines for high yielding GS-CHO processes. In GodiaF,FusseneggerM, editors,Animal cell Technology meets Genomics, Dordrecht: Springer; 2005: 701704.
  • 24
    Birch JR,Racher AJ. Antibody production. Adv Drug Del Rev. 2006; 58: 671685.
  • 25
    Bebbington CR,Renner G,Thompson S,King D,Abrams D,Yarranton GT. High level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology. 1992; 10: 169175.
  • 26
    Lonberg N,Taylor LD,Harding FA,Trounstine M,Higgins KM,Schramm SR,Kuo C,Mashayekh R,Wymore K,McCabe JG,Munoz-O'Regan D,O'Donnell SL,Lapachet ESG,Bengoechea T,Fishwild DM,Carmack CE,Kay RM,Huszar D. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature. 1994; 368: 856859.
  • 27
    Fishwild DM,O'Donnell SL,Bengoechea T,Hudson DV,Harding F,Bernhard SL,Jones D,Kay RM,Higgins KM,Schramm SR,Lonberg N. High-avidity human IgG-Kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotech. 1996; 14: 845850.
  • 28
    Habersetzer F,Fournillier A,Dubuisson J,Rosa D,Abrignani S,Wychowski C,Nakano I,Trepo C,Desgranges C,Inchauspe G. Characterization of Human Monoclonal Antibodies Specific to the Hepatitis C Virus Glycoprotien E2 with In Vitro Binding Neutralization Properties. Virology. 1998; 249: 3241.
  • 29
    Chirino AJ,Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol. 2004; 22: 13831391.
  • 30
    Umana P,Jean-Mairet J,Moudry R,Amstutz H,Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxicity activity. Nat Biotechnol. 1999; 17: 176180.
  • 31
    Yamane-Ohnuki N,Kinoshita S,Inoue-Urakubo M,Kusunoki M,Iida S,Nakano R,Wakitani M,Niwa R,Sakurada M,Uchida K,Shitara K,Satoh M. Establishment of FUT8 Knockout Chinese hamaster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng, 2004; 87: 614622.
  • 32
    Mori K,Kuni-Kamochi R,Yamane-Ohnuki N,Wakitani M,Yamano K,Imai H,Kanda Y,Niwa R,Iida S,Uchida K,Shitara K,Satoh M. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng. 2004; 88: 901908.
  • 33
    Warnock DW,Bai X,Autote K,Gonzales J,Kinealy K,Yan B,Qian J,Stevenson T,Zopf D,Bayer RJ. In Vitro galactosylation of human IgG at 1 Kg scale using recombinant galactosyltransferase. Biotechnol Bioeng. 2005; 92: 831842.
  • 34
    Peipp M,Lammerts van Bueren J,Bleeker W,Dechant M,Beyer T,van Berkel PHC,Parren PWHI,van de Winkel JGJ,Valerius T. Antibody Fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood. In press.
  • 35
    Montano RF,Morrison SL. Influence of the isotype of the light chain on the properties of IgG. J Immunol Methods. 2002; 168: 224231.
  • 36
    Siemiatkoski J,Lyubarskaya Y,Houde D,Tep S,Mhatre RA. Comparison of three techniques for quantitative carbohydrate analysis used in characterization of therapeutic antibodies. Carbohydr Res. 2006; 341: 410419.
  • 37
    Keren Ofir YB,Benhar I,Azriel-Rosenfeld R,Lamed R,Barak Y,Bayer EA,Morag E. Versatile protein microarray based on carbohydrate-binding modules. Proteomics. 2005; 5: 18061814.
  • 38
    Fotinopoulou A,Meyers T,Varley P,Turner S. Screening for glycosylation changes on recombinant human IgG using lectin methods. Biotechnol Appl Biochem. 2003; 37: 17.
  • 39
    Kuno A,Uchiyama N,Koseki-Kuno S,Ebe Y,Takashima S,Yamada M,Hirabayashi J. Evanescent-field fluorescence-assisted lectin microarray: a new strategy for glycan profiling. Nat Methods. 2005; 2: 851856.
  • 40
    Ebe Y,Kuno A,Uchiyama N,Koseki-Kuno S,Yamada M,Sato T,Narimatsu H,Hirabayashi J. Application of Lectin Microarray to Crude Samples: Differential Glycan Profiing Of Lec Mutants. J Biochem. (Tokyo). 2006; 139: 323327.